Nitsan Halevy
Chief Tech/Sci/R&D Officer chez PLURI INC.
Profil
Nitsan Halevy is currently the Chief Medical Officer at Pluri, Inc. Prior to this, she worked as the Chief Development Officer at Quark Pharmaceuticals, Inc. She holds a doctorate degree from Ben-Gurion University of the Negev.
Postes actifs de Nitsan Halevy
| Sociétés | Poste | Début |
|---|---|---|
| PLURI INC. | Chief Tech/Sci/R&D Officer | 01/03/2021 |
Anciens postes connus de Nitsan Halevy
| Sociétés | Poste | Fin |
|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | - |
Formation de Nitsan Halevy
| Ben-Gurion University of the Negev | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PLURI INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
